Professor Robert Lustig, a professor of Pediatric Endocrinology, is giving a presentation on non-alcoholic fatty liver disease (NAFLD) and its connection to chronic diseases like type 2 diabetes. NAFLD affects a significant portion of the population without their knowledge. Dr. Lustig emphasizes the importance of understanding the cause and pathogenesis of this disease, as it has become prevalent even in children who don’t consume alcohol. He challenges the notion that obesity alone is the primary cause of metabolic diseases, presenting data showing that lean individuals also suffer from these conditions. He explains that the measurement of fat on the scale does not accurately determine a person’s health status. Dr. Lustig highlights the significance of insulin resistance as a key factor in determining the development of diabetes and other chronic diseases. He discusses the different fat depots in the body, namely subcutaneous fat and visceral fat, and how their distribution and metabolic activity affect health outcomes. Dr. Lustig considers sugar (glucose-fructose) as a hazardous substance that can alter one metabolic pathway and help develop fatty liver.
we encourage everyone to also watch other YouTube videos of Dr. Lustig on Emery Pharma channel:
About Emery Pharma:
Emery Pharma is a full-service contract research laboratory, supporting the end-to-end development of small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more.
Emery Pharma’s premium services include analytical, bioanalytical solutions, microbiology & cell biology services, drug and impurity characterization, and general R&D and cGMP/GLP support.
At Emery Pharma, our focus is to find innovative solutions for our Clients’ toughest challenges and tailoring those solutions to fit each Client’s unique needs. Our experienced scientific team will manage the process: from drug discovery, proof-of-concept, data management, data analysis, to gathering insights. The team excels at solving scientific challenges, and addressing any issues early in the process, so Clients don’t experience unnecessary setbacks.
Emery Pharma’s experienced chemists and biologists deploy state-of-the-art technology. Instrumentation ranges from high-resolution mass spec (Orbitrap), Triple quad LC-MS/MS, GC-MS, Preparative HPLC, and 400 MHz multinuclear NMR.
Contact us: [email protected]
https://emerypharma.com/
kewords:
Emery Pharma Speaker Series
Professor Lustig
Pediatric Endocrinology
Sugar: The Bitter Truth
metabolica
Non-alcoholic fatty liver disease
Silent killer
Pathogenesis
Type 2 diabetes
Lean diabetes
Normal weight
Risk factor
Metabolic disease
Metabolically healthy obese
Metabolically healthy
Obesity pandemic
Chronic disease
BMI
Growth hormone receptor mutation
The Little Women of Loha
Larone dwarfism
Insulin resistance
Lipodystrophy
Adipose tissue
Visceral fat
Subcutaneous fat
Metabolic Health
Waist circumference
Acute stress
Norepinephrine
Beta-3 adrenergic receptor
Lipolysis
Triglyceride
source
